Format

Send to

Choose Destination
J Med Econ. 2016 Nov;19(11):1049-1055. Epub 2016 Jun 1.

Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data.

Author information

1
a Division of Gastroenterology , Department of Internal Medicine, Hyogo College of Medicine , Hyogo , Japan.
2
b Milliman Inc , Tokyo , Japan.
3
c Global Medical Affairs - Japan, Takeda Pharceutical Company Limited , Tokyo , Japan.
4
d Department of Pharmacoepidemiology , Graduate School of Medicine and Public Health, Kyoto University , Kyoto , Japan.

Abstract

OBJECTIVES:

Published reports have shown the prevalence and incidence of gastroesophageal reflux disease (GERD) is increasing in Japan. The objective of this study is to examine change in GERD incidence, and to understand current patient demographics, medical costs, treatment status, and the suitability of current treatment based on analysis of an insurance claims database.

METHODS:

An insurance claims database with data on ∼1.9 million company employees from January 2005 to May 2015 was used. Prevalence, demographics, and medical costs were analyzed by cross-sectional analysis, and incidence and treatment status were analyzed by longitudinal analysis among newly-diagnosed GERD patients.

RESULTS:

GERD prevalence in 2014 was 3.3% among 20-59 year-olds, accounting for 40,134 people in the database, and GERD incidence increased from 0.63% in 2009 to 0.98% in 2014. In 2014, mean medical cost per patient per month for GERD patients aged 20-59 was JPY 31,900 (USD 266 as of January 2016), which was ∼2.4-times the mean national healthcare cost. The most frequently prescribed drugs for newly-diagnosed GERD patients were proton pump inhibitors (PPIs). Although PPIs were prescribed more often in patients with more doctor visit months, over 20% of patients that made frequent doctor visits (19 or more visits during a 24 calendar months period) were prescribed PPIs during only 1 calendar month or not at all.

LIMITATIONS:

The database included only reimbursable claims data and, therefore, did not cover over-the-counter drugs. The database also consisted of employee-based claims data, so included little data on people aged 60 years and older.

CONCLUSIONS:

Given the increasing incidence of GERD in Japan there is a need for up-to-date information on GERD incidence. This study suggests that some GERD patients may not be receiving appropriate treatment according to Japanese guidelines, which is needed to improve symptom control.

KEYWORDS:

Claims database analysis; Gastroesophageal reflux disease; Health economics; Histamine H2 receptor antagonist; Proton pump inhibitor

PMID:
27207316
DOI:
10.1080/13696998.2016.1192551
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center